使用213Bi的靶向α治疗。

Targeted alpha therapy with 213Bi.

作者信息

Morgenstern Alfred, Bruchertseifer Frank, Apostolidis Christos

机构信息

European Commission, Joint Research Centre, Institute for Transuranium Elements, PO Box 2340, 76125 Karlsruhe, Germany.

出版信息

Curr Radiopharm. 2011 Oct;4(4):295-305. doi: 10.2174/1874471011104040295.

DOI:10.2174/1874471011104040295

PMID:22202152

Abstract

The potential of targeted therapy with the alpha emitter 213Bi has been successfully demonstrated in a large number of preclinical studies and several clinical trials have provided evidence for its feasibility, safety and therapeutic efficacy. This review describes methods for the production of 225Ac and 225Ac/213Bi radionuclide generators, gives an overview of selected preclinical studies and summarizes the current clinical experience with 213Bi.

摘要

α发射体213Bi靶向治疗的潜力已在大量临床前研究中得到成功证明，多项临床试验也为其可行性、安全性和治疗效果提供了证据。本综述描述了225Ac和225Ac/213Bi放射性核素发生器的生产方法，概述了选定的临床前研究，并总结了目前213Bi的临床经验。